{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:26:51Z","timestamp":1789244811049,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Israeli Scientific Foundation","award":["16\/1419"],"award-info":[{"award-number":["16\/1419"]}]},{"name":"Sister-Institution-Network-Funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00262-019-02382-0","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T14:03:23Z","timestamp":1568037803000},"page":"1493-1500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma"],"prefix":"10.1007","volume":"68","author":[{"given":"Jason","family":"Roszik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettai","family":"Markovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Dobosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Layani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Slabodnik-Kaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erez N.","family":"Baruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Ben-Betzalel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raanan","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehezkel","family":"Sidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Schachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Shapira-Frommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Avni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Markel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5487-3750","authenticated-orcid":false,"given":"Raya","family":"Leibowitz-Amit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,9]]},"reference":[{"key":"2382_CR1","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889\u20131894","journal-title":"J Clin Oncol"},{"key":"2382_CR2","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390:1853\u20131862","journal-title":"Lancet"},{"key":"2382_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345\u20131356","journal-title":"N Engl J Med"},{"key":"2382_CR4","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H et al (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375:1845\u20131855","journal-title":"N Engl J Med"},{"key":"2382_CR5","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S et al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378:1789\u20131801","journal-title":"N Engl J Med"},{"key":"2382_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377:1824\u20131835","journal-title":"N Engl J Med"},{"key":"2382_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707\u2013723","journal-title":"Cell"},{"key":"2382_CR8","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3389\/fimmu.2017.01597","volume":"8","author":"ZY Xu-Monette","year":"2017","unstructured":"Xu-Monette ZY, Zhang M, Li J, Young KH (2017) PD-1\/PD-L1 blockade: have we found the key to unleash the antitumor immune response? Front Immunol 8:1597","journal-title":"Front Immunol"},{"key":"2382_CR9","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1182\/blood-2004-10-3944","volume":"105","author":"J Dannull","year":"2005","unstructured":"Dannull J, Nair S, Su Z, Boczkowski D, DeBeck C, Yang B et al (2005) Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 105:3206\u20133213","journal-title":"Blood"},{"key":"2382_CR10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaci.2004.11.004","volume":"115","author":"JK Burgess","year":"2005","unstructured":"Burgess JK, Blake AE, Boustany S, Johnson PRA, Armour CL, Black JL et al (2005) CD40 and OX40 ligand are increased on stimulated asthmatic airway smooth muscle. J Allergy Clin Immunol 115:302\u2013308","journal-title":"J Allergy Clin Immunol"},{"key":"2382_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ et al (2016) Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352:189\u2013196","journal-title":"Science"},{"key":"2382_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603\u2013607","journal-title":"Nature"},{"key":"2382_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0968-0004(01)01995-8","volume":"27","author":"JL Bodmer","year":"2002","unstructured":"Bodmer JL, Schneider P, Tschopp J (2002) The molecular architecture of the TNF superfamily. Trends Biochem Sci 27:19\u201326","journal-title":"Trends Biochem Sci"},{"key":"2382_CR14","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.str.2006.06.015","volume":"14","author":"DM Compaan","year":"2006","unstructured":"Compaan DM, Hymowitz SG (2006) The crystal structure of the costimulatory OX40-OX40L complex. Structure\u00a014:1321\u20131330","journal-title":"Structure"},{"key":"2382_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.humimm.2007.03.012","volume":"68","author":"K Kondo","year":"2007","unstructured":"Kondo K, Okuma K, Tanaka R, Zhang LF, Kodama A, Takahashi Y et al (2007) Requirements for the functional expression of OX40 ligand on human activated CD4+\u2009and CD8+ T cells. Hum Immunol 68:563\u2013571","journal-title":"Hum Immunol"},{"key":"2382_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.immuni.2015.05.012","volume":"42","author":"C Jacquemin","year":"2015","unstructured":"Jacquemin C, Schmitt N, Contin-Bordes C, Liu Y, Narayanan P, Seneschal J et al (2015) OX40 ligand contributes to human lupus pathogenesis by promoting T follicular helper response. Immunity 42:1159\u20131170","journal-title":"Immunity"},{"key":"2382_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2017-07-741025","volume":"131","author":"SL Buchan","year":"2018","unstructured":"Buchan SL, Rogel A, Al-Shamkhani A (2018) The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood 131:39\u201348","journal-title":"Blood"},{"key":"2382_CR18","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1158\/0008-5472.CAN-03-3911","volume":"64","author":"S Andarini","year":"2004","unstructured":"Andarini S, Kikuchi T, Nukiwa M, Pradono P, Suzuki T, Ohkouchi S et al (2004) Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res 64:3281\u20133287","journal-title":"Cancer Res"},{"key":"2382_CR19","doi-asserted-by":"crossref","first-page":"46173","DOI":"10.18632\/oncotarget.10068","volume":"7","author":"C-A Shin","year":"2016","unstructured":"Shin C-A, Cho H-W, Shin A-R, Sohn H-J, Cho H-I, Kim T-G (2016) Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy. Oncotarget 7:46173\u201346186","journal-title":"Oncotarget"},{"key":"2382_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41467-018-08123-8","volume":"10","author":"S Chen","year":"2019","unstructured":"Chen S, Fan J, Zhang M, Qin L, Dominguez D, Long A et al (2019) CD73 expression on effector T cells sustained by TGF-\u03b2 facilitates tumor resistance to anti-4-1BB\/CD137 therapy. Nat Commun 10:150","journal-title":"Nat Commun"},{"key":"2382_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00262-011-1119-y","volume":"61","author":"K Garrison","year":"2012","unstructured":"Garrison K, Hahn T, Lee WC, Ling LE, Weinberg AD, Akporiaye ET (2012) The small molecule TGF-\u03b2 signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol Immunother 61:511\u2013521","journal-title":"Cancer Immunol Immunother"},{"key":"2382_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jtho.2018.03.002","volume":"13","author":"ER Parra","year":"2018","unstructured":"Parra ER, Villalobos P, Zhang J, Behrens C, Mino B, Swisher S et al (2018) Immunohistochemical and image analysis-based study shows that several immune checkpoints are Co-expressed in non-small cell lung carcinoma tumors. J Thorac Oncol 13:779\u2013791","journal-title":"J Thorac Oncol"},{"key":"2382_CR23","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/2326-6066.CIR-15-0228","volume":"4","author":"G Fromm","year":"2016","unstructured":"Fromm G, de Silva S, Giffin L, Xu X, Rose J, Schreiber TH (2016) Gp96-Ig\/costimulator (OX40L, ICOSL, or 4-1BBL) combination vaccine improves T-cell priming and enhances immunity, memory, and tumor elimination. Cancer Immunol Res (Internet) 4:766\u2013778","journal-title":"Cancer Immunol Res (Internet)"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02382-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02382-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02382-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T23:09:11Z","timestamp":1599520151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02382-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["2382"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02382-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"21 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no relevant conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We analyzed the publicly available TCGA and CCLE databases. Use of these data does not mandate patient informed consent. The retrospective data analysis of patient samples was approved by the institutional review board of the Sheba medical center, Tel Hashomer, Israel (Approval # SMC-2411\/15).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"All patients signed an informed consent allowing the analysis and publication of anonymized data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}